Ocular Therapeutix IncOcular Therapeutix Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The ESG rating covers 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Partnerships for the Goals'. The webpage contains a Q&A table about Ocular Therapeutix Inc. Detailed Sustainability analysis of Ocular Therapeutix Inc can be reached by signing in.

Ocular Therapeutix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.

SDG Transparency Score for Ocular Therapeutix Inc 

0.0

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Ocular Therapeutix Inc 
0.0

Environmental

0.0

Social

0.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1967Hospira Inc
0.3
Low
1967PRA Health Sciences Inc
0.3
Low
1970Ocular Therapeutix Inc
0.0
Low
1970CSPC Innovation Pharmaceutical Co Ltd
0.0
Low
1970CTC Bio Inc
0.0
Low
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Ocular Therapeutix Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc offer flexible work?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Ocular Therapeutix Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose water use targets?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Ocular Therapeutix Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Ocular Therapeutix Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Ocular Therapeutix Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose its waste policy?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose energy use targets?

LockedSign up for free to unlock

Does Ocular Therapeutix Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Ocular Therapeutix Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Ocular Therapeutix Inc
These potential risks are based on the size, segment and geographies of the company.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Sorry!

Failed to process!